Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives - Bill of Health
Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives - Bill of Health
Are the incentive mechanisms for orphan drug development working as they should?
Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives - Bill of Health
Orphan Drugs in Oncology
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies - KFF Health News
Health Justice as the Lodestar of Incremental Health Reform - Bill of Health
Abuses of Government Programs and Regulations - Drug Pricing Lab
Incentives - Bill of Health
How Orphan Drugs Became a Highly Profitable Industry
How Orphan Drugs Became a Highly Profitable Industry
Salami-slicing, precision medicine and the Orphan Drug Act
Salami-slicing, precision medicine and the Orphan Drug Act
ICER Publishes White Paper Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage - ICER
13. Incentivising the Development of Global Public Goods for Health, Ready for the Next Crisis? Investing in Health System Resilience
Frontiers Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
GHB, Orphans, and REMS: A Regulatory Love Story (Part 1)
